Ascentage Pharma Group International (NASDAQ: AAPG; HKG: 6855) announced a strategic research collaboration with Peking University in the field of hematology, with the partnership focusing on hematologic oncology as its entry point to integrate clinical resources with innovative R&D strengths and accelerate the clinical translation of innovative achievements for patients.
Collaboration Snapshot
| Item | Detail |
|---|---|
| Parties | Ascentage Pharma Group International (NASDAQ: AAPG; HKG: 6855) and Peking University |
| Agreement Type | Strategic research collaboration |
| Focus Area | Hematology — with hematologic oncology as the entry point |
| Key Dimensions | Clinical research platform establishment; interdisciplinary talent cultivation; mechanisms for translation of scientific and technological achievements |
| Stated Objective | Jointly build a collaborative innovation system for hematologic oncology and accelerate clinical translation of innovative achievements |
| Announcement Date | 15 Sep 2026 |
| Financial Terms | Not disclosed |
Collaboration Framework & Scope
- Clinical Research Platforms: The two parties will establish joint clinical research platforms in hematologic oncology, designed to connect early‑stage discovery directly to clinical investigation.
- Interdisciplinary Talent: A core pillar of the partnership is the cultivation of interdisciplinary talent, pairing university scientific training with industry drug‑development expertise.
- Translation Mechanisms: The collaboration will build dedicated mechanisms for translating scientific and technological achievements into clinical practice, addressing a long‑standing bottleneck in China’s academic‑to‑industry innovation pipeline.
- Resource Integration: Peking University’s clinical and academic resources will be combined with Ascentage Pharma’s innovative R&D capabilities to form a full‑chain collaborative innovation system.
Strategic Context
- Hematologic Oncology Leadership: Ascentage Pharma is a China‑based global biopharmaceutical company with an established franchise in blood cancers, anchored by its commercialized BCL‑2 inhibitor program and pipeline targeting mechanisms such as BCR‑ABL and MDM2‑p53 — positioning it as a natural industry partner for a hematology‑focused academic alliance.
- Peking University’s Research Base: Peking University ranks among China’s leading comprehensive research institutions, with top‑tier medical schools and affiliated hospitals providing deep clinical populations and translational research infrastructure in hematology.
- Industry‑Academia Model: University–pharma strategic collaborations of this type are increasingly favored in China’s innovation policy environment, aiming to shorten the path from bench to bedside in high‑unmet‑need therapeutic areas.
- Patient Impact: By accelerating clinical translation in hematologic oncology, the partnership targets faster delivery of novel therapies to patients with blood cancers — a disease area where treatment options remain limited for relapsed and refractory populations.
Market Impact & Outlook
- Pipeline Acceleration: The collaborative innovation system is designed to speed the clinical translation of early discoveries, potentially enriching Ascentage Pharma’s hematology pipeline with academically originated assets.
- Talent Moat: Joint cultivation of interdisciplinary researchers supports long‑term R&D productivity and strengthens the company’s scientific bench in a competitive talent market.
- Dual‑Listing Visibility: As a dual‑listed company on NASDAQ and HKEX, Ascentage Pharma’s high‑profile academic partnership reinforces its innovation narrative for global investors.
- Next Steps: Specific research programs, funding commitments and milestone timelines were not disclosed; further details are expected as the collaboration matures.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the strategic research collaboration between Ascentage Pharma and Peking University, including expectations around platform development, talent cultivation, and the clinical translation of research achievements. Actual results may differ materially due to risks including execution of the collaboration, research and clinical outcomes, competitive dynamics, and changes in regulatory or funding environments.-Fineline Info & Tech
